High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC
Introduction Despite significant successes, immune checkpoint blockade fails to achieve clinical responses in a significant proportion of patients, predictive markers for responses are imperfect and immune-related adverse events (irAEs) are unpredictable. We used T-cell receptor (TCR) sequencing to...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/12/e008950.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584947931545600 |
|---|---|
| author | Alexandre Reuben Mehmet Altan Latasha Little Jianjun Zhang Ajay Sheshadri Hai T Tran Mara B Antonoff Stephen G Swisher John V Heymach Saumil Gandhi Natalie Vokes Ziyi Li Ruoxing Li Runzhe Chen Joshua Baguley Jefferson Sinson Greg Lizee |
| author_facet | Alexandre Reuben Mehmet Altan Latasha Little Jianjun Zhang Ajay Sheshadri Hai T Tran Mara B Antonoff Stephen G Swisher John V Heymach Saumil Gandhi Natalie Vokes Ziyi Li Ruoxing Li Runzhe Chen Joshua Baguley Jefferson Sinson Greg Lizee |
| author_sort | Alexandre Reuben |
| collection | DOAJ |
| description | Introduction Despite significant successes, immune checkpoint blockade fails to achieve clinical responses in a significant proportion of patients, predictive markers for responses are imperfect and immune-related adverse events (irAEs) are unpredictable. We used T-cell receptor (TCR) sequencing to systematically analyze prospectively collected patient blood samples from a randomized clinical trial of dual immune checkpoint inhibitor therapy to evaluate changes in the T-cell repertoire and their association with response and irAEs.Methods Patients with immunotherapy-naïve metastatic non-small cell lung cancer (NSCLC) were treated with ipilimumab and nivolumab according to trial protocol (LONESTAR, NCT03391869). Blood samples were systematically obtained at baseline (n=107), after 12 weeks of ipilimumab and nivolumab (n=91), and at the time of grade ≥2 irAEs (n=77). For analysis of T-cell repertoire, we performed immunoSEQ to assess the complementary determining region 3β region of the TCR involved in antigen binding.Results A total of 250 samples from 119 patients were analyzed. Patients who had a response to therapy exhibited greater T-cell diversity at baseline. Interestingly, patients with irAEs demonstrated lower T-cell richness at the time of toxicity compared with those without irAEs.Conclusion Our study highlights the potential impact of peripheral blood T-cell repertoire on clinical response and toxicities from the combination of ipilimumab and nivolumab in patients with metastatic NSCLC. These findings suggest that analysis of peripheral blood T-cell repertoire may help to guide patient selection for treatment with ipilimumab and nivolumab.Trial registration number NCT03391869. |
| format | Article |
| id | doaj-art-a11582d449cf465abfcc34bec7605e1d |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-a11582d449cf465abfcc34bec7605e1d2025-01-27T07:50:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-12-01121210.1136/jitc-2024-008950High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLCAlexandre Reuben0Mehmet Altan1Latasha Little2Jianjun Zhang3Ajay Sheshadri4Hai T Tran5Mara B Antonoff6Stephen G Swisher7John V Heymach8Saumil Gandhi9Natalie Vokes10Ziyi Li11Ruoxing Li12Runzhe Chen13Joshua Baguley14Jefferson Sinson15Greg Lizee16Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA1The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA4Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Thoracic and Cardivascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Thoracic and Cardivascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USARadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAMelanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAIntroduction Despite significant successes, immune checkpoint blockade fails to achieve clinical responses in a significant proportion of patients, predictive markers for responses are imperfect and immune-related adverse events (irAEs) are unpredictable. We used T-cell receptor (TCR) sequencing to systematically analyze prospectively collected patient blood samples from a randomized clinical trial of dual immune checkpoint inhibitor therapy to evaluate changes in the T-cell repertoire and their association with response and irAEs.Methods Patients with immunotherapy-naïve metastatic non-small cell lung cancer (NSCLC) were treated with ipilimumab and nivolumab according to trial protocol (LONESTAR, NCT03391869). Blood samples were systematically obtained at baseline (n=107), after 12 weeks of ipilimumab and nivolumab (n=91), and at the time of grade ≥2 irAEs (n=77). For analysis of T-cell repertoire, we performed immunoSEQ to assess the complementary determining region 3β region of the TCR involved in antigen binding.Results A total of 250 samples from 119 patients were analyzed. Patients who had a response to therapy exhibited greater T-cell diversity at baseline. Interestingly, patients with irAEs demonstrated lower T-cell richness at the time of toxicity compared with those without irAEs.Conclusion Our study highlights the potential impact of peripheral blood T-cell repertoire on clinical response and toxicities from the combination of ipilimumab and nivolumab in patients with metastatic NSCLC. These findings suggest that analysis of peripheral blood T-cell repertoire may help to guide patient selection for treatment with ipilimumab and nivolumab.Trial registration number NCT03391869.https://jitc.bmj.com/content/12/12/e008950.full |
| spellingShingle | Alexandre Reuben Mehmet Altan Latasha Little Jianjun Zhang Ajay Sheshadri Hai T Tran Mara B Antonoff Stephen G Swisher John V Heymach Saumil Gandhi Natalie Vokes Ziyi Li Ruoxing Li Runzhe Chen Joshua Baguley Jefferson Sinson Greg Lizee High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC Journal for ImmunoTherapy of Cancer |
| title | High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC |
| title_full | High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC |
| title_fullStr | High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC |
| title_full_unstemmed | High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC |
| title_short | High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC |
| title_sort | high peripheral t cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic nsclc |
| url | https://jitc.bmj.com/content/12/12/e008950.full |
| work_keys_str_mv | AT alexandrereuben highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT mehmetaltan highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT latashalittle highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT jianjunzhang highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT ajaysheshadri highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT haittran highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT marabantonoff highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT stephengswisher highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT johnvheymach highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT saumilgandhi highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT natalievokes highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT ziyili highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT ruoxingli highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT runzhechen highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT joshuabaguley highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT jeffersonsinson highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc AT greglizee highperipheraltcelldiversityisassociatedwithlowerriskoftoxicityandsuperiorresponsetodualimmunecheckpointinhibitortherapyinpatientswithmetastaticnsclc |